CA2377299A1 - Mesalazine controlled release oral pharmaceutical compositions - Google Patents

Mesalazine controlled release oral pharmaceutical compositions Download PDF

Info

Publication number
CA2377299A1
CA2377299A1 CA002377299A CA2377299A CA2377299A1 CA 2377299 A1 CA2377299 A1 CA 2377299A1 CA 002377299 A CA002377299 A CA 002377299A CA 2377299 A CA2377299 A CA 2377299A CA 2377299 A1 CA2377299 A1 CA 2377299A1
Authority
CA
Canada
Prior art keywords
pharmaceutical compositions
oral pharmaceutical
release oral
controlled release
mesalazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002377299A
Other languages
French (fr)
Other versions
CA2377299C (en
Inventor
Roberto Villa
Massimo Pedrani
Mauro Ajani
Lorenzo Fossati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cosmo Technologies Ltd
Original Assignee
Cosmo S.P.A.
Roberto Villa
Massimo Pedrani
Mauro Ajani
Lorenzo Fossati
Cosmo Technologies Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11383159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2377299(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cosmo S.P.A., Roberto Villa, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati, Cosmo Technologies Limited filed Critical Cosmo S.P.A.
Publication of CA2377299A1 publication Critical patent/CA2377299A1/en
Application granted granted Critical
Publication of CA2377299C publication Critical patent/CA2377299C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Controlled-release oral pharmaceutical compositions containing as active ingredient 5-amino-salicylic acid, com-prising:
a) an inner lipophilic matrix consisting of substances with melting point below 90 °C in which the active ingredient is at least partly inglobated; b) an outer hydrophilic matrix in which the lipophilic matrix is dispersed; c) optionally other excipients.
CA002377299A 1999-06-14 2000-06-08 Mesalazine controlled release oral pharmaceutical compositions Expired - Lifetime CA2377299C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI99A001316 1999-06-14
IT1999MI001316A ITMI991316A1 (en) 1999-06-14 1999-06-14 ORAL PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE OF MESALAZINE
PCT/EP2000/005321 WO2000076481A1 (en) 1999-06-14 2000-06-08 Mesalazine controlled release oral pharmaceutical compositions

Publications (2)

Publication Number Publication Date
CA2377299A1 true CA2377299A1 (en) 2000-12-21
CA2377299C CA2377299C (en) 2009-05-12

Family

ID=11383159

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002377299A Expired - Lifetime CA2377299C (en) 1999-06-14 2000-06-08 Mesalazine controlled release oral pharmaceutical compositions

Country Status (18)

Country Link
US (1) US6773720B1 (en)
EP (2) EP1287822B1 (en)
JP (2) JP4727875B2 (en)
CN (2) CN1217665C (en)
AT (2) ATE324104T1 (en)
AU (1) AU5077200A (en)
CA (1) CA2377299C (en)
DE (2) DE60001835T2 (en)
DK (2) DK1198226T3 (en)
ES (2) ES2262749T3 (en)
HK (2) HK1046247B (en)
IT (1) ITMI991316A1 (en)
MX (1) MXPA01012888A (en)
NO (1) NO329402B1 (en)
PT (2) PT1198226E (en)
RU (1) RU2245148C2 (en)
TR (1) TR200200561T2 (en)
WO (1) WO2000076481A1 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1183014T3 (en) 1999-06-14 2004-02-09 Cosmo Spa Flavored controlled release oral pharmaceutical compositions
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
AR036797A1 (en) 2001-10-15 2004-10-06 Ferring Bv A METHOD TO PREPARE A PHARMACEUTICAL COMPOSITION THAT INCLUDES 5-AMINOSALICILIC ACID TO USE IN THE TREATMENT OF ULCEROSE COLITIS AND CROHN DISEASES
US9308220B2 (en) 2001-12-11 2016-04-12 Cosmo Technologies Limited Pharmaceutical compositions for the oral administration of heparin or derivatives thereof
ITMI20012599A1 (en) 2001-12-11 2003-06-11 Cosmo Spa PHARMACEUTICAL COMPOSITIONS FOR THE ORAL ADMINISTRATION OF HEPARINE OR DERIVATIVES, USEFUL FOR THERAPY OF INFLAMMATORY DISEASES OF THE INT
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
KR100540035B1 (en) * 2002-02-01 2005-12-29 주식회사 태평양 Multi-stage oral drug controlled-release system
FR2852843B1 (en) * 2003-03-24 2008-05-23 Karim Ioualalen GALENIC SYSTEM FOR MASKING TASTE
WO2004093883A2 (en) * 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
GB0322848D0 (en) * 2003-09-30 2003-10-29 Alpharma Ltd Tetracycline controlled release pharmaceutical dosage form
AU2004312059A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Atomoxetine formulations
US7417037B2 (en) * 2004-01-20 2008-08-26 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
EP2046389A2 (en) 2006-07-19 2009-04-15 The Board of Regents of the University of Texas System Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease
MX2009002786A (en) * 2006-09-13 2009-03-30 Procter & Gamble Methods of treatment for ulcerative colitis using aminosalicylate.
BRPI0622008A2 (en) * 2006-09-13 2011-12-20 Procter & Gamble Treatment Methods for Ulcerative Colitis
US20100035850A1 (en) 2006-11-17 2010-02-11 Shire Development Inc. Method of treatment for inflammatory bowel disease
FR2913884A1 (en) * 2007-03-21 2008-09-26 Oralance Pharma Sa NON-IONIZABLE HYDROPHOBIC GALENIC SYSTEM
US20090028944A1 (en) * 2007-07-16 2009-01-29 Balaji Sathurappan Pharmaceutical compositions comprising mesalamine
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US20090169622A1 (en) * 2007-12-27 2009-07-02 Roxane Laboratories, Inc. Delayed-release oral pharmaceutical composition for treatment of colonic disorders
CA2765033C (en) 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
EP2488163A1 (en) 2009-10-16 2012-08-22 Ranbaxy Laboratories Limited A delayed release pharmaceutical composition of mesalamine
IT1398643B1 (en) 2010-03-04 2013-03-08 Cosmo Technologies Ltd SOLID COMPOSITION FOR ORAL ADMINISTRATION OF DYES, AND DIAGNOSTIC USE OF THE SAME
EP2425826A1 (en) * 2010-09-01 2012-03-07 Disphar International B.V. Mesalazine tablet having improved dissolution
IT1402047B1 (en) * 2010-10-19 2013-08-28 Cross Pharma Sa USE OF MEXIPROSTIL IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES
EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
ES2834986T3 (en) 2011-01-07 2021-06-21 Anji Pharma Us Llc Chemosensory receptor ligand-based therapies
US9795792B2 (en) 2011-02-25 2017-10-24 Medtronic, Inc. Emergency mode switching for non-pacing modes
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
KR20200137035A (en) 2012-01-06 2020-12-08 앤지 파마 유에스 엘엘씨 Biguanide compositions and methods of treating metabolic disorders
NZ626578A (en) 2012-01-06 2016-11-25 Elcelyx Therapeutics Inc Compositions and methods for treating metabolic disorders
EP2822542A1 (en) * 2012-03-07 2015-01-14 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
WO2013144176A1 (en) 2012-03-30 2013-10-03 Laboratorios Del Dr. Esteve, S.A. Controlled release formulatin comprising mesalamine
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
CA2878625A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EP2722058A1 (en) 2012-10-19 2014-04-23 Cosmo Technologies Ltd Solid oral composition containing dyes for use in endoscopic diagnosis
SG11201505240QA (en) 2013-01-05 2015-08-28 Elcelyx Therapeutics Inc Delayed-release composition comprising biguanide
PT2959892T (en) * 2013-02-22 2020-12-15 Zeria Pharm Co Ltd Enteric coated tablet
US9763887B2 (en) 2013-03-15 2017-09-19 Allergan Pharmaceuticals International Limited Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
CN104922090B (en) * 2015-07-03 2017-11-14 湖南方盛制药股份有限公司 Mesalazine enteric sustained-release pellet
EP3162362A1 (en) 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimized high-dose tablet of mesalazine
ITUA20162293A1 (en) 2016-04-05 2017-10-05 Sofar Spa Process for solid formulations of mesalazine
RU2019118459A (en) 2016-11-28 2020-12-28 Космо Текнолоджиз Лтд. SOLID PERORAL COMPOSITION CONTAINING DYES
US10098898B1 (en) 2017-12-04 2018-10-16 Handa Pharmaceuticals, Llc Release stable mesalamine dosage forms
EP3501503A1 (en) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Solid delivery composition
EP3662895A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
IT201800011120A1 (en) 2018-12-14 2020-06-14 Dpl Pharma S P A SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF MESALAZINE OR ITS DERIVATIVES
CN112587506A (en) * 2020-12-09 2021-04-02 南京森博医药研发有限公司 Method for preparing mesalazine enteric sustained-release capsule

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921757A (en) * 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
JPS6248618A (en) * 1985-08-27 1987-03-03 Zeria Shinyaku Kogyo Kk Slow-releasing drug preparation and production thereof
JP2893191B2 (en) * 1988-11-08 1999-05-17 武田薬品工業株式会社 Controlled release matrix agent
IL92343A0 (en) * 1988-12-20 1990-07-26 Gist Brocades Nv Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them
IL92344A0 (en) * 1989-01-04 1990-07-26 Gist Brocades Nv Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules
JPH02282323A (en) * 1989-04-21 1990-11-19 Shin Etsu Chem Co Ltd Production of sustained release tablet
JPH03232814A (en) * 1990-02-08 1991-10-16 Shin Etsu Chem Co Ltd Production of sustained release tablet
IE61651B1 (en) * 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
GB2253346A (en) * 1991-02-22 1992-09-09 John Rhodes Delayed release oral dosage forms for treatment of intestinal disorders
JP3011752B2 (en) * 1990-10-23 2000-02-21 フロイント産業株式会社 Sustained-release preparation and method for producing the same
JP2829794B2 (en) * 1991-02-08 1998-12-02 エスエス製薬 株式会社 Orally administered pranoprofen formulation for sustained release
JPH0624962A (en) * 1992-07-09 1994-02-01 Green Cross Corp:The Enteric sustained release solid pharmaceutical preparation
EP0665010B1 (en) * 1992-10-16 2002-09-11 Nippon Shinyaku Company, Limited Method of manufacturing wax matrices
US5911980A (en) * 1996-06-27 1999-06-15 Macrochem Corporation Lipophilic and amphiphilic or hydrophilic film-forming polymer compositions, and use thereof in topical agent delivery system and method of delivering agents to the skin
AU5775398A (en) * 1996-12-17 1998-07-15 Poli Industria Chimica S.P.A. Site-specific controlled release dosage formulation for mesalamine
US5851555A (en) 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
DK1183014T3 (en) * 1999-06-14 2004-02-09 Cosmo Spa Flavored controlled release oral pharmaceutical compositions

Also Published As

Publication number Publication date
TR200200561T2 (en) 2002-06-21
PT1198226E (en) 2003-07-31
CA2377299C (en) 2009-05-12
JP2010024241A (en) 2010-02-04
CN100448448C (en) 2009-01-07
EP1287822A2 (en) 2003-03-05
DE60001835D1 (en) 2003-04-30
PT1287822E (en) 2006-07-31
HK1046247B (en) 2006-04-07
DE60027608T2 (en) 2007-04-26
DE60001835T2 (en) 2003-11-13
US6773720B1 (en) 2004-08-10
CN1355694A (en) 2002-06-26
HK1085669A1 (en) 2006-09-01
JP5235839B2 (en) 2013-07-10
CN1720919A (en) 2006-01-18
ES2194732T3 (en) 2003-12-01
ITMI991316A1 (en) 2000-12-14
NO20016107L (en) 2002-02-11
ATE235234T1 (en) 2003-04-15
AU5077200A (en) 2001-01-02
DK1198226T3 (en) 2003-07-21
DE60027608D1 (en) 2006-06-01
CN1217665C (en) 2005-09-07
MXPA01012888A (en) 2002-07-30
ATE324104T1 (en) 2006-05-15
RU2245148C2 (en) 2005-01-27
JP2003501458A (en) 2003-01-14
EP1287822A3 (en) 2003-03-19
JP4727875B2 (en) 2011-07-20
NO329402B1 (en) 2010-10-11
HK1046247A1 (en) 2003-01-03
EP1198226A1 (en) 2002-04-24
ES2262749T3 (en) 2006-12-01
ITMI991316A0 (en) 1999-06-14
DK1287822T3 (en) 2006-08-28
EP1287822B1 (en) 2006-04-26
WO2000076481A1 (en) 2000-12-21
EP1198226B1 (en) 2003-03-26
NO20016107D0 (en) 2001-12-14

Similar Documents

Publication Publication Date Title
CA2377299A1 (en) Mesalazine controlled release oral pharmaceutical compositions
EP2322146A3 (en) Microcapsule formulations comprising two pharmaceutically active ingredients
CA2385890A1 (en) Controlled release compositions comprising nimesulide
CA2307018A1 (en) Osmotic medicament releasing system
CA2123160A1 (en) Controlled release formulation
CA2389235A1 (en) Controlled release hydrocodone formulations
CA2232450A1 (en) Oral pharmaceutical composition containing antimicrobial actives and sustained release pantoprazole
CA2102630A1 (en) Pharmaceutical compositions of compacted medicaments
IE871584L (en) Sustained release capsule.
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
AU764280C (en) Process for the preparation of pellets with a content of up to 90 wt. per cent of a pharmaceutical active ingredient
AU1351788A (en) Slow-release pharmaceutical agent
DE60020501D1 (en) Trimetazidine-containing matrix tablet for prolonged release of active ingredient after oral administration
AU4903700A (en) Chronotherapeutic diltiazem formulations and the administration thereof
DE60006362D1 (en) CAPSULES WITH COMPOSITIONS CONTAINING LORATADINE AND PSEUDOEPHEDRIN
CA2216277A1 (en) Controlled release pharmaceutical compositions for the oral administration containing nifedipine as active substance
AU3669700A (en) 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
CA2362769A1 (en) Microcapsules for sustained release of drugs
WO2001070205A3 (en) Composition comprising paracetamol and niflumic acid
ITMI20000972A0 (en) PHARMACEUTICAL FORMULATIONS, WITH MODIFIED RELEASE, WITH HIGH BIOAVAILABILITY, CONTAINING ACTIVE INGREDIENTS WITH ANTIBIOTIC ACTIVITY.
CA2191855A1 (en) Solid pharmaceutical compositions containing (s)-2-(4-isobutylphenyl)propionic acid active ingredient and microcrystalline cellulose and colloidal silica as excipients
IT1317871B1 (en) Controlled release and taste masking oral compositions comprising active ingredient incorporated in a matrix structure
RU97105420A (en) SOLID DRUG FORM BASED ON SULFAMETOXAZOLE AND TRIMETOPRIM
AU2002323916A1 (en) Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20200608